Supplementary Figure 2 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Authors:

Abstract
MRNA expression of (A) AR and (B) ESR1 and correlations between AR and ESR1 in (C) cohort 1 (no prior advanced ET) and (D) cohort 2 (1 prior advanced ET) *R calculated using a Pearson correlation. Abbreviation: ET, endocrine therapy